Company: SXTPW
Filing Date: 2025-09-05
Form Type: 424B5
Source: 0001213900-25-085050
Chunk: 39

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-09-05
Form: 424B5
Chunk 39
---
.55 per share of our common stock. This represents an immediate decrease in net tangible book
value of $0.073 per share of our common stock to our existing stockholders and an immediate increase of $0.09 per share to purchasers
of common stock in this offering, as illustrated in the following table:

| Assumed public offering price per share                                                                                  |     |   |        |   |     | $ | 1.460 |
| Historical net tangible book value per share as of June 30, 2025                                                         |     | $ |  1.500 |   |     |   |       |
| Pro forma increase in net tangible book value per share attributable to the pro forma adjustments described above        |     |   |  0.123 |   |     |   |       |
| Pro forma net tangible book value per share as of June 30, 2025                                                          |     | $ |  1.623 |   |     |   |       |
| Decrease in pro forma net tangible book value per share after giving effect to the offering                              |     | $ | (0.073 | ) |     |   |       |
| Pro forma as-adjusted net tangible book value per share as of June 30, 2025 after the offering                           |     |   |        |   |     |   | 1.550 |
| Dilution in pro forma as-adjusted net tangible book value per share to new investors after giving effect to the offering |     |   |        |   |     | $ | 0.090 |

The table above assumes for illustrative purposes
that an aggregate of 957,214 shares of common stock are sold at a price of $1.46 per share, the last reported sales price of our common
stock on The Nasdaq Capital Market on September 3, 2025. The shares sold in this offering, if any, will be sold from time to time at various
prices.

The above discussion and table are based on 1,472,891 shares outstanding as of June 30, 2025 (4,104,469 as of June 30, 2025 after giving effect to the pro forma adjustments described above), and excludes:

| ● | 57,068                                                                   
 shares of common stock reserved for future issuance under the 2022 Plan; |

| ● | 7,587,594                                                                                                                             
 shares of common stock issuable upon exercise of outstanding warrants, inclusive